Intellectual Property News & Topics - Secerna LLP

VENCLEXTA®

A to Z: Drugs in Highlight: V is for VENCLEXTA®

News A to Z Feature 30/04/2025

Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.

Read more

Secerna Header Images (3)

Events, News 12/06/2023

Secerna LLP to attend BioFocus 2023 in Newcastle

GB2 4127

Industry news, News, Team news 08/06/2023

Secerna appoints marketing lead to fuel growth

EU Flag UPC article

European, Industry news, News 01/06/2023

New era for European patent law as unified patent system takes effect

AI Image Secerna LLP

Industry news, News 23/05/2023

The UK and the EU: Taking different approaches to AI regulation

Dermot GB2 1498 Nov 22

Events 22/05/2023

Secerna to attend Dublin Tech Summit 2023

B012424

Events 19/05/2023

Secerna to attend Nu-Tech Engineering & Technology Solutions Exhibition

JP3 2550

Events 16/05/2023

Secerna to attend Climb23 festival

Charlotte and Huw image

Events 16/05/2023

Secerna to attend BIO International Convention in Boston, USA

HUGO BURNAND ROYAL HOUSEHOLD 2023

Industry news, News 09/05/2023

What does a new monarch mean for the existing Royal Warrants?

15 16 17 18 19 20 21 22 23 24 25